Sheila Rodriguez Stanley, PhD, FACG

**** ** ***** **

Edmond, OK 73025

Cell: 405-***-****

Office: 405-***-****

Email: cfu8rd@r.postjobfree.com

Objective:

To obtain a Pharma position in Medical Affairs that would allow me to utilize my scientific and clinical expertise, as well as my MSL experience to advance the field of medicine and patient care.

Summary:

• Medical Science Liaison with 4.5 years of experience in the fields of Gastroenterology, Rheumatology/ Nephrology

• 16+ years of Clinical Research in Gastroenterology, including IBD, at a leading GI Clinical trials site

• Proven track record in clinical research/ and publications which has enhanced relationship-building with expert opinion leaders and has improved my overall effectiveness as a Medical Affairs professional in the field, as well as with internal partners, and cross-functionally.

Education:

Texas A&M University, College Station, TX. (1985-1989)

PhD Nutrition/Physiology

Louisiana State University, Baton Rouge, LA (1983-1985)

MS Animal Sciences/Nutrition

Louisiana State University, Baton Rouge, LA (1979-1983)

BS Animal Sciences

Experience:

May 2010 to March 2012: Sr. Clinical Science Liaison-Medical and Scientific Affairs, Takeda Pharmaceuticals North America. Territory: LA, OK, IN. Responsible for establishing, developing and maintaining collaborative relationships with influential members of the medical community to promote awareness and serve as a technical, scientific and medical expert in applicable therapeutic areas and as aligned with Takeda’s products and focus. Products supported included Amitiza, Dexilant, and Uloric, as well as a pipeline product for IBD (vedolizumab).

December 2007 to May 2010: Clinical Science Liaison- Medical and Scientific Affairs, Takeda Pharmaceuticals North America. Territory: OK, KS, MO, MN, ND, SD, IA, NE. Responsible for establishing, developing and maintaining collaborative relationships with influential members of the medical community to promote awareness and serve as a technical, scientific and medical expert in applicable therapeutic areas and as aligned with Takeda’s products and focus. Product support included Amitiza and Dexilant.

o Detailed Clinical Science Liaison Experience with Takeda included Speaker training, Sales training and support, National medical meeting lead, Therapeutic Area Lead (IBD), Slide development committee, IBD functional planning team, CSL team training (IBD, vedolizumab, /esophageal testing), Participated in Advisory groups/advisory workshops, Facilitated Investigator initiated grants, Investigator initiated grant committee and Uloric point, Global target hunting committee, Identification of Clinical Trial Sites, Development of IBD/vedolizumab training curriculum for CSL team.

November 1991 to December 2007: Director, Clinical GI Physiology Laboratory: Oklahoma Foundation for Digestive Research. Performed all Clinical and Research GI testing from November 1991 to 1995, and Supervised Lab technicians from 1995 to December 2007: Clinical tests included: Ano-rectal Manometry, Biofeedback Training, Esophageal Manometry, 24-h pH monitoring, Provocative testing for GERD and Functional Heartburn/Chest Pain, Gastric Emptying, Hydrogen and Methane Breath testing. Additional experience: Certified Clinical Research Coordinator (CCRC), Designed/wrote numerous research protocols (Investigator-initiated Pharma-funded and internally funded), Attended/presented data at annual GI scientific meetings (DDW, ACG, ANMS), Authored numerous abstracts and publications.

Additional Work Experience:

June 1989 to August 1991: Postdoctoral Research Fellow, USDA ARS, Forage and Livestock Research Laboratory, El Reno, OK 73036. Research Assignment: To determine the effects of oral cysteamine on inhibition of somatostatin release in the GI tract.

September 1988 to May 1989: Laboratory Animal Care Technician, Animal Science Department, Texas A&M University, College Station.

January 1986 to August 1988: Graduate Research and Teaching Assistant, Animal Science Department, Texas A & M University, College Station.

January 1984 to December 1985: Graduate Research Assistant, Animal Science Department, Louisiana State University, Baton Rouge.

September 1979 to December 1983: Laboratory Assistant, Feed and Fertilizer Laboratory, Louisiana State University, Baton Rouge.

Awards/Memberships/Honors:

Association of Rheumatology Health Professionals

Crohn’s and Colitis Foundation of America, Professional Member

Federation of Clinical Immunology Societies

American College of Gastroenterology Governor’s Award for Excellence in Clinical Research- Oct 2007

Fellow of the American College of Gastroenterology

American Motility Society

Functional Brain-Gut Research Group

American Gastroenterological Association

Numerous Recognition awards at Takeda for Leadership, Teamwork, Results Driven, and Business Acumen

Publications: Abstracts

1. Decktor, D. L., M. Robinson, S. L. Rodriguez, R. Narayanan, P. N. Maton . H2 - Receptor Antagonist tolerance and Gastroesophageal Reflux Disease: An assessment of intraesophageal and intragastric pH during 28 days of Standard Therapy. Gastroenterology 1993; 104:A64.

2. Rodriguez, S., Decktor, D., Robinson, M., Maton, P. Dual site ambulatory pH monitoring and gastroesophageal reflux disease: A pH electrode catheter across the lower esophageal sphincter does not alter esophageal acid exposure. Gastroenterology 1993;104:180.

3. Decktor, D., Robinson, M. Maton, P., Rodriguez, S. H2-Receptor antagonist tolerance and gastroesophageal reflux disease: A comparison of nizatidine, ranitidine, and famotidine on esophageal and gastric pH over 28 days of standard therapy. Am J Gastroenterol 1993;88(9):1487.

4. Rodriguez, S., Decktor, D., Robinson, M., Maton, P. Does a topical anesthetic such as Dyclonine alter rectal sensitivity and pain perception in patients with IBS? Am J Gastroenterol 1993; 88(9):1582.

5. Chelikani S, Robinson M, Maton P, Rodriguez S, Decktor D. Comparison of tablet versus liquid antacids on acidity in the esophagus and stomach. Am J Gastroenterol 1995; 90(9): 1570.

6. Greenwood B, Rodriguez SL, Maton PN, Robinson M, Pappa K, Wiltham L, Giefer EL, Sirgo M. A comparison of three provocative meals: Effects on intraesophageal pH and heartburn symptoms. Gastroenterology 1996; 110(4):A123.

7. Robinson M, Earnest DE, Maton PN, Greenwood B, Rodriguez, Jaffe P, Silver MT, Kleoudis CS, Sue, SO. Frequent heartburn symptoms should not be ignored in subjects who self-treat with antacids. Gastroenterology 1996;110(4):A241.

8. Robinson M, Maton PN, Rodriguez SL, Greenwood B, Humphries T. Effects of a new proton pump inhibitor, Rabeprazole Sodium (E3880) on esophageal and gastric pH in patients with gastroesophageal reflux disease (GERD). Gastroenterology 1996; 110(4):A240.

9. Rodriguez S L, Greenwood B,Tyler K, Nasr F, McRorie J. Telemetric monitoring of distal colonic motility in the mini-pig: Applications for colonic motility studies in patients. Gastroenterology 1996; 110(4):A746.

10. Earnest, D., Robinson, M., Jaffe, M.D., Maton, P.N., Greenwood, B., Rodriguez, S., Silver, M.A., Hammer, A., Sue, S. In subjects with frequent heartburn who self-medicate with antacids, ranitidine 150 mg. twice daily is superior to PRN antacids in relieving symptoms and healing erosive esophagitis. Am J Gastroenterol 1996;91(9):A23.

11. Robinson, M., Earnest, D., Greenwood, B., Maton, P. N., Rodriguez, S., Jaffe, P., Silver,M. T., Kleoudis, C. S., and Sue, S. O. Chronic antacid use may indicate significant esophageal pathology and motor dysfunction. American Motility Society. Digestive Diseases and Science 1996.

12. Robinson M, Earnest DL, Maton PN, Greenwood B, Rodriguez SL, Jaffe P, Perill R, Miner PB. Cisapride plus lifestyle modifications significantly improve heartburn in symptomatic GERD. Gastroenterology 1997; 112:A270.

13. Rodriguez SL, Robinson M, Earnest DL, Maton PN, Miner PB, Kleoudis C, Silver MT, Sue SO. Esophageal hypersensitivity: A major cause of heartburn? Gastroenterology 1997; 112:A270.

14. Robinson M, Earnest DL, Maton PN, Greenwood B, and Rodriguez S. Cisapride is superior to antacids for first line heartburn treatment. Am J Gastroenterol 1997; 92(9);A1601

15. Robinson M, Rodriguez-Stanley S, Filinto J, Zubaidi S, Miner PB, McIsaac R, and Ciociola A. Bedtime ranitidine vs. omeprazole for control of nocturnal acid. Gastroenterology 1998;114(4):A268.

16. Earnest DL, Robinson M, Rodriguez-Stanley S, Ciociola A. Daily or severe heartburn predicts a favorable response to ranitidine 150 mg b.i.d. in otherwise healthy antacid users. Gastroenterology 1998; 114(4):A111.

17. Rodriguez-Stanley, S, Miner PB, Robinson M, Filinto J, and Zubaidi S. Reflux variation in the one hour postprandial period. Gastroenterology 1998; 114(4):A269.

18. Robinson M, Rodriguez-Stanley S, Miner PB, Filinto J, Zubaidi S, McIsaac R, and Ciociola A. Ranitidine 75 mg hs is superior to omeprazole for controlling nocturnal acid breakthrough in patients receiving omeprazole once daily. Digestion 1998;59 (Suppl 3):580.

19. Robinson M, Rodriguez-Stanley S, Miner PB, Filinto J, Zubaidi S, McIsaac R, Pappa K, and Ciociola A. Zantac 75Ô = Prilosec 20 mgÔ to block nighttime acid! Am J Gastroenterol 1998;93(9):1623.

20. Rodriguez-Stanley S, Robinson M, Filinto J, Zubaidi S, Albrecht HH, Mandel KG, and Miner PB. Peak esophageal acid exposure determines timing of prn therapy. Am J Gastroenterol 1998; 93(9):1623.

21. Rodriguez-Stanley S, Robinson M, and Miner PB. Case Study: “A pheasant stuck in my throat!” Am J Gastroenterol 1998; 93(9):1623.

22. Rodriguez-Stanley S, Collings KL, Filinto J, Zubaidi S, Robinson M, and Miner PB. A pH threshold of 4.0 underestimates gastroesophageal reflux! Gastroenterology 1999; 116 (4): A293.

23. Rodriguez-Stanley S, Collings KL, Robinson M, Filinto J, Zubaidi S, and Miner PB. Single Dose prokinetic therapy does not enhance gastric emptying or reduce gastroesophageal reflux following a high fat, high calorie, heartburn-provoking meal. Gastroenterology 1999; 116 (4): A294.

24. Rodriguez-Stanley S, Collings KL, Robinson M, Filinto J, Zubaidi S, and Miner PB. Capsaicin: Effects on symptoms, reflux, and gastric emptying. Gastroenterology 1999; 116 (4): A293.

25. Robinson M, Rodriguez-Stanley S, McIsaac R, Pappa K, Begun J, Ciociola A, and Miner PB. How do antacids differ? Gastroenterology 1999; 116 (4): A292.

26. Robinson M, Rodriguez-Stanley S, Earnest D, Sloan S, DeLoria C, Miner PB. Cisapride: effective for heartburn in the community. Am J Gastroenterol 1999; 94 (9): 2598.

27. Pratt P, Collings K, Rodriguez-Stanley S, Robinson M, Bemben M, Balm TK, Miner PB. Heartburn in cyclists: correlations with esophageal acidity. Am J Gastroenterol 1999; 94 (9): 2599.

28. Pratt P, Collings K, Rodriguez-Stanley S, Hardesty B, Robinson M, Bemben M, Miner PB. Epidemiology of gastrointestinal symptoms in athletes. Am J Gastroenterol 1999; 94 (9): 2596.

29. Robinson M, Rodriguez-Stanley S, Bullard F, Neeley D, Clark J, McRorie J, Miner PB. Psyllium normalizes stool consistency in diarrhea-predominant IBS. Am J Gastroenterol 1999; 94 (9): 2684.

30. Collings K, Rodriguez-Stanley S, Robinson M, Carryl O, Bagchi D, Miner PB. Pepto-Bismol administered prior to provocative foods improves symptoms of dyspepsia. Am J Gastroenterol 1999; 94 (9): 2616.

31. Pratt P, Collings K, Rodriguez-Stanley S, Robinson M, Bemben M, Balm TK, Miner PB. Weightlifting induces pathological reflux. Am J Gastroenterol 1999; 94 (9): 2599.

32. Rodriguez-Stanley S, Robinson M, Filinto J, Zubaidi S, Ciociola A, Miner PB. Zantac 75 plus a chewable antacid provides superior acid control. Am J Gastroenterol 1999; 94 (9): 2599.

33. Rodriguez-Stanley S, Robinson M, Parrott D, Chacko G, and Miner PB. Distribution of oral and rectal markers in active Crohn’s colitis: Implications for therapy. Gastroenterology 2000; 118(4):A6215.

34. Collings K, Rodriguez-Stanley S, Pratt P, Robinson M, Bemben M, Balm TK, Miner PB. Competitive distance running increases gastroesophageal reflux. Gastroenterology 2000; 118(4):A2592.

35. Robinson M, Rodriguez-Stanley S, Gardner JD, Ciociola AA, Filinto J, Zubaidi S, Miner PB. In GERD patients taking a morning dose of omeprazole, bedtime low-dose ranitidine is equivalent to bedtime omeprazole for inhibition of nocturnal gastric acidity. Gastroenterology 2000; 118(4):A5934.

36. Gardner JD, Rodriguez-Stanley S, Robinson M, Filinto J, Zubaidi S, Miner PB. Relationship between esophageal acid exposure and heartburn severity in meal-induced heartburn. Gastroenterology 2000; 118(4):A2607.

37. Gardner JD, Rodriguez-Stanley S, Robinson M, Filinto J, Zubaidi S, Miner PB. How do provocative meals cause heartburn? Integrated gastric acidity as the determinant of esophageal acid exposure. Gastroenterology 2000; 118(4):A2605.

38. Gardner JD, Rodriguez-Stanley S, Robinson M, Filinto J, Zubaidi S, Miner PB. Meal-induced heartburn: Quantification of esophageal acid exposure and its relationship to gastric acidity. Gastroenterology 2000; 118(4):A2606.

39. Gardner JD, Robinson M, Rodriguez-Stanley S, Miner PB. Identification of a novel, beneficial action of proton pump inhibitors in GERD. Gastroenterology 2000; 118(4):A5661.

40. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB. Complementary therapy for heartburn: Low dose ranitidine plus calcium carbonate antacid. Gastroenterology 2000; 118(4):A2631.

41. Rodriguez-Stanley S, Robinson M, Ciociola AA, Filinto J, Zubaidi S, Miner PB, Gardner J. Esophageal acid sensitivity modulates response to acid reducing therapy in postprandial heartburn. Am J Gastroenterology 2000; 95(9):A72.

42. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB, Gardner J. Integrated acidity and heartburn severity determine timing of self-medication in postprandial heartburn. Am J Gastroenterology 2000; 95(9):A74.

43. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB, Gardner J. Integrated acidity: a novel technique demonstrating synergy between low dose ranitidine and antacid for acid reduction and relief of meal-induced heartburn. Am J Gastroenterology2000; 95(9):A73.

44. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB, Gardner J. Direct neutralization of esophageal acid by antacid in meal-induced heartburn. Am J Gastroenterology 2000; 95(9):A71.

45. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB, Gardner J. Self-medication for postprandial heartburn: determined by heartburn severity. Gut 2000; 47(Suppl.III):A57.

46. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB, Gardner J. Antacid effects are oesophageal, not gastric. Gut 2000; 47(Suppl.III):A57..

47. Rodriguez-Stanley S, Robinson M, Ciociola AA, Filinto J, Zubaidi S, Miner PB, Gardner J. Efficacy of acid reduction therapy depends on oesophageal acid sensitivity. Gut 2000; 47(Suppl.III):A58.

48. Collings K, Rodriguez-Stanley S, Robinson M, Proskin H, Miner PB. A novel antacid formulation: pH effects of calcium carbonate-containing chewing gum. Gastroenterology 2001; 120:A2224.

49. Rodriguez-Stanley S, Robinson M, Miner PB. Colonic distribution of oral and rectal markers in IBD. Gastroenterology 2001; 120:A15.

50. Collings K, Rodriguez-Stanley S, Robinson M, Proskin H, Miner PB. Antacid chewing gum: a new antacid formulation that relieves heartburn. Am J Gastroenterology 2001; 96(9):A24.

51. Rodriguez-Stanley S, Miner PB. Esophageal sensitivity to barostat balloon distention and bernstein acid infusion: which test is best? Am J Gastroenterology 2001; 96(9):A103.

52. Gardner JD, Rodriguez-Stanley S, Robinson M, Miner P. The role of gastric potassium channels KCNQ1 in meal-stimulated gastric acid secretion and the pathophysiology of gastroesophageal reflux disease. Gastroenterology 2002; 122 (4):A113.

53. Zubaidi S, Rodriguez-Stanley S, Ciociola A, Miner PB. Relationship between wall tension and compliance in patients with symptomatic reflux. Gastroenterology 2002; 122(4):A358.

54. Gardner JD, Rodriguez-Stanley S, Robinson M, Miner P. Integrated acidity is superior to time pH <4 in quantifying data from gastric and esophageal pH recordings. Gastroenterology 2002; 122 (4):A579.

55. Rodriguez-Stanley S, Zubaidi S, Ciociola A, Miner P. Wide spectrum of symptoms produced by barostat balloon distention of the esophagus in patients presenting with varied upper GI complaints. Am J Gastroenterology 2002; 97(9):A72.

56. Rodriguez-Stanley S, Zubaidi S, Ciocioa A, Miner P. Barostat balloon distention of the esophagus: pressure-ramp vs. volume-step for determination of sensation and pain thresholds. Am J Gastroenterology 2002; 97(9):A73.

57. Rodriguez-Stanley S, Zubaidi S, Ciociola A, Miner P. Are patients with functional heartburn sensitive to both mechanical and chemical stimuli? Am J Gastroenterology 2002; 97(9):A115.

58. Gardner J, Rodriguez-Stanley S, Robinson M, Sloan S, Miner P. Characterization of the abnormality in esophageal acid exposure in gastroesophageal reflux disease. Am J Gastroenterology 2002; 97(9):A1

59. Gardner J, Rodriguez-Stanley S, Robinson M, Sloan S, Miner P. Increased postprandial gastric acidity is a major pathophysiologic abnormality in gastroesophageal reflux disease. Am J Gastroenterology 2002; 97(9):A2.

60. Rodriguez-Stanley S, Ahmed T, Zubaidi S, Riley S, Miner P. Luminal calcium from chewable antacidsimproves esophageal function. Gastroenterology 2003; 124(4 Suppl 1):A109.

61. Rodriguez-Stanley S, Ciociola A, Bochenek W, Zubaidi S, Miner PB. Ranitidine 150 mg rapidly increases pain threshold and decreases symptom severity with acid infusion in patients with functional heartburn. Gastroenterology 2003; 124(4Suppl 1):A221.

62. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Riley S, Miner PB. Effect of intraesophageal perfusion of chenodeoxycholic acid in patients with non-erosive gastroesophageal reflux. Am J Gastroenterology 2003; 98(9):A23.

63. Rodriguez-Stanley S, Zubaidi S, Riley S, Miner PB. Visceral sensitivity in functional heartburn is not organ specific. Am J Gastroenterology 2003; 98(9):A27.

64. Redinger N, Siddiqui A, Rodriguez-Stanley S, Miner PB. Intrasubject physiologic variability in 24 hour esophageal exposure. Am J Gastroenterology 2003; 98(9):A56.

65. Rodriguez-Stanley S, Wolff M, Siddiqui A, Proskin H, Miner PB. Psychological profile and QOL in patients with functional heartburn. Gastroenterology 2004; 126(Suppl2):A601.

66. Rodriguez-Stanley S, Zubaidi S, Proskin H, Miner PB. Reliability of esophageal balloon distention and bernstein measurements in patients with functional heartburn. Gastroenterology 2004; 126(Suppl2): A323.

67. Rodriguez-Stanley S, Wolff M, Proskin H, Miner PB. Gastrointestinal symptom profile in patients with functional heartburn. Gastroenterology 2004; 126(Suppl2):A380.

68. Rodriguez-Stanley S, Zubaidi S, Riley S, Miner PB. Gastric infusion of HCI is a novel test for dyspepsia. Gastroenterology 2004; 126(Suppl2):A439.

69. Rodriguez-Stanley S, Zubaidi S, Wolff M, Riley S, Proskin H, Miner Pb P Jr. Tegaserod significantly improves esophageal mechanical pain threshold, regurgitation, and global preference vs. placebo in patients with functional heartburn. Gastroenterology 2004;127:331.

70. Redinger N, Zubaidi S, Bemben D, Rodriguez-Stanley S, Miner PB Jr. Effect of esophageal acid exposure on exercise tolerance before and after 8 and 12 weeks of rabeprazole 20 mg a day in subjects with a history of heartburn. Gastroenterology 2005; 128(4 Suppl 2):A61.

71. Rodriguez-Stanley S, Zubaidi S, Proskin HM, Kralstein JR, Miner PB Jr. Tegaserod significantly improves several upper gastrointestinal dysmotility symptoms in patients with functional heartburn. Gastroenterology 2005; 128(4 Suppl 2):A530.

72. Rodriguez-Stanley S, Wolff M, Proskin HM, Bottoli I, Kralstein J, Miner PB. An exploratory open label trial of Tegaserod in non-erosive GERD patients with incomplete response to PPIs. Am J Gastroenterology 2005; 100(9):S38(A46).

73. Rodriguez-Stanley S, Redinger N, Miner PB Jr. Effect of Naprosyn on Gastric Acid Secretion and Gastric pH. Gastroenterology 2006; 130(4 Suppl 2):M1982(A388).

74. Cointepas J, Rodriguez-Stanley S, Riley S, Miner PB Jr. Importance of duodenal biopsies in patients with suspected upper GI pathology. Am J Gastroenterology 2006; 101(9):S515(A1344).

75. Rodriguez-Stanley S, Riley S, Zubaidi S, Miner PB Jr. Symptom response to standard antibiotic therapy in patients with high breath methane. Am J Gastroenterology 2006; 101(9):S204(A479).

76. Rodriguez-Stanley S, Bottoli I, Zubaidi S, Riley S, Adams T, Wolff M, Miner PB, Jr. Gastric and esophageal sensory parameters in patients with functional dyspepsia and functional heartburn. Am J Gastroenterology 2006, 101(9):S477(A1230).

77. Rodriguez-Stanley S, Riley S, Zubaidi S, Philip B Miner. The Added Value of Esophageal Balloon Distention and Bernstein Acid Infusion to High Resolution Manometry in a Clinical Practice Setting. Gastroenterology 2007; 132(4 Suppl 2):S1957(A287).

78. Rodriguez-Stanley S, Bottoli I, Proskin H, Zubaidi S, Riley S, Adams T, Wolff M, Miner PB. The Effects of Tegaserod 6 Mg Bid On Gastrointestinal Symptoms in Patients with Functional Dyspepsia and Accompanying Heartburn. Gastroenterology 2007; 132(4 Suppl 2):S1873(A269).

79. Muhammad Hasan, Sheila Rodriguez-Stanley, Susan Riley, Sattar Zubaidi and Philip B Miner, Jr. Are There Differences in Sensitivity Thresholds to Balloon Distention in the Upper and Lower Esophagus? Am J Gastroenterology 2007. Abstract

80. Sheila Rodriguez-Stanley, Susan Riley and Philip B Miner, Jr. Case Report: Zantac 300 mg BID Controls Gastric Acid Secretion vs Nexium 75 mg BID in a Patient With Gastric Bypass and Clinically Significant Vomiting. Am J Gastroenterology 2007. Abstract

81. Muhammad Hasan, Sheila Rodriguez-Stanley, Susan Riley, Sattar Zubaidi and Philip B Miner, Jr. Comparison of Esophageal Motility Parameters as Measured by the New High Resolution Manometry (HRM) vs Traditional Manometry (TM). Am J Gastroenterology 2007. Abstract

82. Sheila Rodriguez-Stanley, Maggie Wolff, Tisha Adams and Philip B Miner, Jr. High Cortisol Levels are Correlated to Low Esophageal Pain Threshold to Balloon Distention in Patients With NERD and Functional Heartburn. Am J Gastroenterology 2007. Abstract

Publications: Manuscripts

1. Rodriguez SL, Craig WM, Hembry FG. Changes in ruminal concentrations of microbial ammonia and amino acids due to monensin and time. J Anim Sci. 1986; 63:1990-1995.

2. Cole NA, Gallavan RH, Rodriguez SL, Purdy CW. Influence of triiodothyronine injections on calf immune response to an infectious bovine rhinotracheitis virus challenge and nitrogen balance of lambs. J Anim Sci. 1994; 72:1263-73.

3. Greenwood, B, Rodriguez S, Decktor D, Maton PN, Robinson M. Irritable bowel syndrome: a study to investigate the mechanism(s) of visceral hypersensitivity. J Okla State Med Assoc. 1996; 89:47-50.

4. Decktor DL, Krawet SH, Rodriguez SL, Robinson M, Castell DO. Dual site ambulatory pH monitoring: a probe across the lower esophageal sphincter does not induce gastroesophageal reflux. Am J Gastroenterol. 1996; 91:1162-1166.

5. Robinson M, Maton, PN, Rodriguez S, Greenwood B, Humphries TJ. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11:973-980.

6. Robinson M, Earnest D, Rodriguez-Stanley S, Greenwood-Van Meerveld B, Jaffe P, Silver MT, Kleoudis CS, Wilson LE, Murdock RH. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med. 1998 Nov 23; 158:2373-2376.

7. Rodriguez S, Miner P, Robinson M, Greenwood B, Maton PN, Pappa K. Meal type affects heartburn severity. Dig Dis Sci. 1998; 43:485-490.

8. Rodriguez-Stanley S, Robinson M, Earnest DL, Greenwood-Van Meerveld B, Miner PB Jr. Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol. 1999; 94:628-631.

9. Rodriguez-Stanley S, Robinson M, Biscopink RJ, Miner PB Jr. Pheasant-induced dysphagia. Dig Dis Sci. 2000; 45:1743-1746

10. Earnest D, Robinson M, Rodriguez-Stanley S, Ciociola AA, Jaffe P, Silver MT, Kleoudis CS, Murdock RH. Managing heartburn at the 'base' of the GERD 'iceberg': effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids. Aliment Pharmacol Ther. 2000; 14:911-918.

11. Rodriguez-Stanley S, Collings KL, Robinson M, Owen W, Miner PB Jr. The effects of capsaicin on reflux, gastric emptying and dyspepsia. Aliment Pharmacol Ther. 2000; 14:1291-1234.

12. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB Jr, Gardner JD. Synergy between low-dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal-induced heartburn. Aliment Pharmacol Ther. 2001; 15:1365-1374.

13. Gardner JD, Rodriguez-Stanley S, Robinson M. Integrated acidity and the pathophysiology of gastroesophageal reflux disease. Am J Gastroenterol. 2001; 96:1363-1370.

14. Collings KL, Rodriguez-Stanley S, Proskin HM, Robinson M, Miner PB Jr. Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal pH control. Aliment Pharmacol Ther. 2002 ;16:2029-2035.

15. Gardner JD, Rodriguez-Stanley S, Robinson M, Miner PB Jr. Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002; 16:1819-1829.

16. Gardner JD, Perdomo C, Sloan S, Hahne WF, Barth JA, Rodriguez-Stanley S, Robinson. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther. 2002; 16:455-464.

17. Robinson M, Rodriguez-Stanley S, Miner PB, McGuire AJ, Fung K, Ciociola AA. Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn. Aliment Pharmacol Ther. 2002; 16:435-443.

18. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB Jr, Gardner JD. Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole. Dig Dis Sci. 2002; 47:265-273.

19. Collings KL, Pierce Pratt F, Rodriguez-Stanley S, Bemben M, Miner PB. Esophageal reflux in conditioned runners, cyclists, and weightlifters. Med Sci Sports Exerc. 2003; 35:730-735.

20. Rodriguez-Stanley S, Ciociola A, Zubaidi S, Proskin HM, Miner PB Jr. A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn. Aliment Pharmacol Ther. 2004 Nov 1;20(9):975-82.

21. Rodriguez-Stanley S, Ahmed T, Zubaidi S, Riley S, Akbarali HI, Mellow MH, Miner PB. Calcium carbonate antacids alter esophageal motility in heartburn sufferers. Dig Dis Sci. 2004 Nov-Dec;49(11-12):1862-7.

22. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci. 2005 Jan;50(1):81-5.

Contact this candidate